Summary
Phase 1 of this study will evaluate the safety and tolerability of 177Lu-FAP-2286 and determine the recommended Phase 2 dose (RP2D) in patients with advanced solid tumors. Phase 2 of this study is designed to evaluate objective response rate (ORR) in tumor-specific cohorts of patients with a FAP-expressing solid tumor.
Official Title
LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid Tumor
Keywords
Solid Tumor, 177Lu-FAP-2286, 68Ga-FAP-2286, theranostic, FAP-2286, FAP, fibroblast activation protein, dosimetry, CAF, cancer-associated fibroblasts, Peptide-Targeted Radioligand Therapy, PTRT, Peptide Receptor RadionuclideTherapy, PRRT, TRT, Targeted radioligand therapy, Target radionuclide therapy, Lutetium-177, Gallium-68, Neoplasms, Specific Solid Tumors